Zoetis (NYSE:ZTS) Now Covered by Leerink Partners

Leerink Partners assumed coverage on shares of Zoetis (NYSE:ZTS - Free Report) in a research report report published on Monday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $215.00 target price on the stock.

Several other analysts have also commented on ZTS. Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the stock an "overweight" rating in a report on Wednesday, August 14th. Stifel Nicolaus lifted their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a "buy" rating in a report on Wednesday, September 18th. Argus raised shares of Zoetis to a "strong-buy" rating in a report on Friday, August 9th. JPMorgan Chase & Co. upped their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Finally, BTIG Research raised their target price on Zoetis from $220.00 to $225.00 and gave the company a "buy" rating in a research report on Monday, August 12th. Eleven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $220.80.

Zoetis Stock Performance

ZTS traded up $1.56 during trading on Monday, reaching $176.81. 2,380,621 shares of the company's stock were exchanged, compared to its average volume of 2,545,031. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis has a 1 year low of $144.80 and a 1 year high of $201.92. The company's fifty day simple moving average is $183.83 and its 200-day simple moving average is $180.97. The stock has a market capitalization of $79.77 billion, a P/E ratio of 33.24, a price-to-earnings-growth ratio of 2.69 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion during the quarter, compared to analysts' expectations of $2.29 billion. During the same quarter last year, the company posted $1.36 earnings per share. The firm's revenue was up 11.6% compared to the same quarter last year. As a group, research analysts predict that Zoetis will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. Zoetis's dividend payout ratio is presently 32.52%.

Institutional Investors Weigh In On Zoetis

Several hedge funds and other institutional investors have recently bought and sold shares of ZTS. Peapack Gladstone Financial Corp raised its position in shares of Zoetis by 1.8% during the 3rd quarter. Peapack Gladstone Financial Corp now owns 77,004 shares of the company's stock valued at $15,045,000 after buying an additional 1,393 shares during the period. Tidal Investments LLC lifted its stake in shares of Zoetis by 3.4% in the 3rd quarter. Tidal Investments LLC now owns 15,210 shares of the company's stock valued at $2,972,000 after purchasing an additional 500 shares during the last quarter. Destination Wealth Management grew its holdings in shares of Zoetis by 0.8% during the 3rd quarter. Destination Wealth Management now owns 123,844 shares of the company's stock worth $24,197,000 after purchasing an additional 1,027 shares during the period. Wilmington Savings Fund Society FSB increased its position in shares of Zoetis by 801.0% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 18,606 shares of the company's stock worth $3,635,000 after purchasing an additional 16,541 shares during the last quarter. Finally, World Investment Advisors LLC raised its holdings in Zoetis by 29.1% in the 3rd quarter. World Investment Advisors LLC now owns 34,236 shares of the company's stock valued at $6,689,000 after buying an additional 7,709 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.